1. Home
  2. G vs KYMR Comparison

G vs KYMR Comparison

Compare G & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genpact Limited

G

Genpact Limited

HOLD

Current Price

$36.81

Market Cap

6.4B

ML Signal

HOLD

Logo Kymera Therapeutics Inc.

KYMR

Kymera Therapeutics Inc.

HOLD

Current Price

$80.25

Market Cap

6.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
G
KYMR
Founded
1997
2015
Country
Bermuda
United States
Employees
140000
N/A
Industry
Professional Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
6.8B
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
G
KYMR
Price
$36.81
$80.25
Analyst Decision
Buy
Strong Buy
Analyst Count
6
26
Target Price
$49.50
$107.72
AVG Volume (30 Days)
1.8M
618.6K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
2.00%
N/A
EPS Growth
9.82
N/A
EPS
3.13
N/A
Revenue
$2,279,438,000.00
$39,211,000.00
Revenue This Year
$9.23
$11.85
Revenue Next Year
$7.26
$7.79
P/E Ratio
$11.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.79
$19.45
52 Week High
$50.71
$103.00

Technical Indicators

Market Signals
Indicator
G
KYMR
Relative Strength Index (RSI) 35.27 49.33
Support Level $34.79 $77.78
Resistance Level $46.04 $95.90
Average True Range (ATR) 1.07 3.64
MACD -0.07 -0.31
Stochastic Oscillator 22.17 53.23

Price Performance

Historical Comparison
G
KYMR

About G Genpact Limited

Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

Share on Social Networks: